Life Sciences Leadership.

Wilson Sonsini has worked with leading life sciences innovators across every industry sector—from biotechnology and diagnostics to medical devices and therapeutics.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than sixty years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Quick Links

Your exports.
Our experience.

More Info About Our Practice

Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts

Upcoming FRE 702 Amendment Reemphasizes the Admissibility Bar for Expert Testimony and Courts’ Gatekeeping Role

News Articles

Firm Earns Top Score in Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index

Newsletters

Sustainability and ESG Advisory Practice Update, November 2023

Leading Matters

Client Highlights

Wilson Sonsini Advises DuploCloud on $32 Million Series B Funding

On November 29, 2023, DuploCloud, an industry pioneer offering a platform engineering solution that encompasses full stack DevOps automation with built-in compliance, closed a $32 million Series B funding round, led by WestBridge Capital and StepStone Group, along with previous investor Mayfield. This latest funding brings the company’s total amount raised to $49.5 million. Wilson Sonsini Goodrich & Rosati advised DuploCloud on the transaction.

Learn More

Client Highlights

Wilson Sonsini Advises IVIVA on Acquisition by United Therapeutics

In October 2023, United Therapeutics acquired all of the outstanding equity of IVIVA Medical, Inc., a spin-out from the Harvard Stem Cell Institute addressing the chronic shortage of organs available for transplant. IVIVA is developing the IVIVA Kidney, a printed matrix cellularized with a patient’s own cells, which aids in the filtration and reabsorption functions of the native kidney.

Learn More

Client Highlights

Firm Advises WuXi XDC on US$470 Million Hong Kong IPO

On November 17, 2023, WuXi XDC Cayman Inc. (WuXi XDC) was successfully listed on the Main Board of the Stock Exchange of Hong Kong, raising approximately HK$3,676 million (US$470 million) from its IPO, or approximately HK$4,070.7 million (US$520.4 million) if the underwriters fully exercise their over-allotment option, making it the third largest IPO and the largest biotech IPO in Hong Kong this year to date. Wilson Sonsini Goodrich & Rosati acted as issuer’s U.S. counsel in the IPO and Hong Kong listing. The firm also acted as the U.S. and Hong Kong counsel of WuXi AppTec Co., Ltd., a controlling shareholder of WuXi XDC (WuXi AppTec), in connection with this transaction.

Learn More

Client Highlights

Wilson Sonsini Advises Divergent Technologies, Inc. on Upsized $230 Million Series D

On November 13, 2023, Divergent Technologies, Inc., the company that has invented, developed, and commercialized the world's first end-to-end digital industrial manufacturing system, announced that it has completed a Series D equity financing totaling $230 million. The round was led by a $100 million investment from Hexagon AB and included participation from new and existing institutional and family office investors. Wilson Sonsini Goodrich & Rosati advised Divergent on the transaction.

Divergent has created the world's first end-to-end software-hardware production system for industrial digital manufacturing—the Divergent Adaptive Production System (DAPS)—allowing customers to design, additively manufacture, and automatically assemble complex structures for automotive, aerospace, and defense applications. DAPS transforms the economics and environmental impact of manufacturing complex structures for vehicles of all types by optimizing designs, dematerializing structures, and eliminating upfront capex.

Learn More

Client Highlights

Wilson Sonsini Advises NTx on $47.5 Million Series B

On November 16, 2023, Nature's Toolbox (NTx), a life sciences company building next generation platforms to manufacture RNA and protein, announced the close of a $47.5 million Series B funding round led by RA Capital Management, with strong participation from existing investors Anzu Partners and BlueStone Venture Partners. Wilson Sonsini Goodrich & Rosati advised NTx on the transaction.

Learn More

Client Highlights

Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio

On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.

Learn More

See More Leading Matters

The Entrepreneurs Report – Q3 2023

In this latest issue of The Entrepreneurs Report, we've compiled a range of data on venture financing transactions and convertible note financings in which the firm was involved in Q3 2023, with the objective of identifying relevant trends in activity and valuation levels for the U.S. venture capital in general. In addition, this issue features an AI regulation update with Joshua Gruenspecht, a member of the firm’s artificial intelligence and machine learning industry group, who discusses the Biden administration’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence.